

7

Trial Affidavit of Deborah DeVaux

**UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS**

IN RE PHARMACEUTICAL INDUSTRY
AVERAGE WHOLESALE PRICE LITIGATION

MDL No. 1456

THIS DOCUMENT RELATES TO:
ALL CLASS ACTIONS

CIVIL ACTION: 01-CV-12257-PBS

Judge Patti B. Saris

TRIAL AFFIDAVIT OF DEBORAH DEVAUX

I, Deborah Devaux, pursuant to 28 U.S.C. § 1746, on oath, depose and state as follows:

1. I am a resident of the Commonwealth of Massachusetts. I have personal knowledge of the facts stated below, would so testify in court if called upon to do so, and am competent to provide testimony.
2. My educational background includes a Bachelors of Arts degree in sociology and education from Western Michigan University in 1979. In 1982, I received a Masters Degree in health care administration from the University of Michigan.
3. I am currently employed at Blue Cross Blue Shield of Massachusetts ("BCBSMA") as Senior Vice President for Health Care Contract Management. I have been employed at BCBSMA for approximately six years. Previous to my current title I held the positions of Senior Director for Provider Contracting and Vice President for Health Care Contract Management at BCBSMA.
4. Prior to my employment at BCBSMA, I held a number of positions in the health care industry. From approximately 1982 to 1984, I was employed by the Veteran's Administration in Boston as an Administrative Fellow. From 1984 to 1988, I was employed at Fallon Community

Health Plan ("Fallon") in its planning and development area. My last title at Fallon was Director of Planning and Development. From 1988 to 1991, I was employed by a health plan known as Rhode Island Group Health Association which was acquired in the early 1990s by Harvard Community Health Plan ("HCHP"). I held a Director level position at HCHP and my responsibilities included both strategic planning and contract management. In that position I was responsible for contracting with providers of all services except retail pharmacies, including physicians, physician groups and hospitals. From approximately 1991 until 1995, I was employed at the New England Medical Center ("NEMC"). Among other responsibilities at NEMC, I was responsible for negotiating the contracts, or supervising those negotiating contracts, on behalf of NEMC with most large regional and national health plans, including HPHC, BCBSMA, Aetna, CIGNA and others. From 1995 until approximately 1998, I was a Senior Manager at Ernst & Young. In that position I worked with clients, both physician groups and insurers, to help them structure contractual relationships between these two types of entities. In 1998 I returned to HPHC as the Director of Contracting. In 2000, I became employed with BCBSMA.

5. My job duties as Senior Vice President for Health Care Contract Management at BCMSMA include setting the overall direction of contracting for all providers (except dentists) and leading or supporting major corporate initiatives in areas such as incentive payment, product development, and policy development.

6. In my employment at BCBSMA, I have had responsibility for establishing contracts between BCBSMA and, among other entities, physicians and physician organizations.

7. I have personally been involved in negotiating such contracts, and in more recent years in supervising staff who negotiate such contracts. It is my experience that reimbursement for

physician administered drugs is typically not a point of negotiation between BCBSMA and physicians. BCBSMA establishes, and periodically updates, fee schedules that govern the amount that any physician or physician organization in the BCBSMA network will be reimbursed both for the physician administered drugs and for the administration fee associated with administration of those drugs to insureds.

8. The fee schedules maintained by BCBSMA are referenced in the contracts with physicians or physician groups. Whenever BCBSMA enters into a contract with a physician or physician group, they are provided the fee schedules maintained by BCBSMA that pertain to their specialty. If a contract with a physician covers multiple years or has an “evergreen” clause – meaning it continues from year to year unless amended or cancelled by one of the parties – the physician or physician group will be notified of fee schedule changes or updates during the contract term.

9. Although I am not responsible for establishing the fee schedules for physician administered drugs, I understand through experience that they are developed by BCBSMA’s Actuarial area using AWP as the basis for reimbursement. Currently, BCBSMA’s reimbursement for physician administered drugs is set at 95% of AWP.

10. In addition to my duties as described above, I am also Chair of the Provider Financial Strategy Work Group (“PFSWG”). This is a working group within BCBSMA that, among other responsibilities, makes policy decisions at BCBSMA that relate to reimbursement to physicians and physician groups for services and for physician administered drugs.

11. In early 2005, the PFSWG considered the fact that the Center for Medicaid Services (“CMS”) had made the decision to move, as of January 2006, away from using AWP as a basis for reimbursement for physician administered drugs and would rely instead on a calculation of

the average sale price ("ASP"). The PFSWG considered an analysis of the impact on BCBSMA of Medicare's new ASP fee schedules using historic utilization data from BCBSMA that was prepared under the supervision of, and presented to the PFSWG by, Michael Mulrey.

12. The analysis that was presented to the PFSWG, attached hereto as Exhibit A (Trial Exhibit _____) indicated that if BCBSMA moved to using Medicare's calculated ASP and Medicare's new schedule for administration fees associated with physician administered drugs that BCBSMA would save a modest amount of money. It was my decision, along with others on the PFSWG, not to move from the AWP based reimbursement schedule to the new ASP reimbursement implemented by Medicare at that time.

13. Generally, as a matter of policy, BCBSMA does not make policy decisions or adopt new benchmarks unless they are well-established and accepted industry-wide. BCBSMA does not consider itself to have any particular expertise in developing the data or science necessary to determine the relative values of different services or drugs and generally uses industry-accepted methodologies whenever possible. PFSWG members agreed to monitor the use of ASP as a basis for reimbursement of physician administered drugs to determine whether it became an accepted standard industry-wide.

14. Members of the PFSWG were also concerned with moving to the use of ASP because it was not clear at the time that Medicare would continue to use ASP on a long-term basis. Members of the PFSWG felt that BCBSMA should not spend time and money in moving to an ASP reimbursement system if there was a possibility that the ASP would be discontinued or that Medicare would adopt a different standard.

15. Until the PFSWG considered the move to ASP, I was unaware of the full magnitude of spreads between the published AWP and the actual sales prices at which physicians can

apparently purchase some of these drugs. In my years of experience negotiating contracts between insurers and physician groups, the basis of reimbursement for physician administered drugs was never raised as a point of negotiation. As far as I know it was also not a subject that was often discussed or widely-known at BCBSMA.

16. I was aware that some physicians or physician groups with large practices who could buy in greater quantities for instance, may have paid less and other doctors may have paid more to acquire these drugs. However, I was not aware that certain drug manufacturers were publishing or causing to be published AWP's that exceeded some of their drugs' actual average sale prices by more than 30% and that they were doing so in order to increase their market share for these drugs at the expense of payors such as BCBSMA. Even when PFSWG was considering whether to follow Medicare and begin using ASP, it was not clear to me which manufacturers were engaged in the inflation of AWP in this way or which drugs were involved.

17. Other than through this litigation, I have not received information about which physician-administered drugs may have had unduly inflated AWP's.

18. In 2005, BCBSMA began to shift its reimbursement methodology for hospitals for physician administered drugs from a percentage-of-charges basis to an AWP-based fee schedule. This change was implemented in order to create greater predictability in the costs for these services. This project was undertaken under my direction and by employees under my supervision. The decision to use AWP was an attempt to employ an industry-accepted methodology. To my knowledge, there was no other widely-accepted methodology or benchmark to use.

19. BCBSMA's decision to employ AWP in its fee schedules with hospitals does not reflect any agreement or acknowledgment that AWP's that are not in fact the average of wholesale prices charged for the drug are fair or correct.

I make the foregoing statements under penalty of perjury on the date written next to my name below.

Date: October 26 2006

Deborah Devaux
Deborah Devaux



Exhibit A



Landmark Center
401 Park Drive
Boston, MA 02215-3326

Analysis of CMS Average Wholesale Price Reform Reimbursement for Part B Drugs

Prepared by:

Actuarial Department

Product and Provider Financial Management

February 7, 2004



Reasons for Reform

- Physicians benefit from the “spread” between AWP and acquisition cost creating an overpayment for drugs and costs for Medicare.
- According to GAO and CMS, in 2001 Medicare overpaid Part B drugs by over \$1 billion.
- In 2002 Oncologists collected approximately \$600 million in overpayments.
- Patients who pay a coinsurance are adversely affected by the inflated AWP

• Source: Committee on Ways and Means, *Medicare Prescription Drug, Improvement, and Modernization Act of 2003*, Chairman Bill Thomas 2/26/2004

Average Sales Price (ASP) Reform

The Medicare Modernization ACT has led to the creation of a new drug pricing system beginning January 1, 2004 to replace Medicare's current pricing system.

- **Phase 1:** CMS move from 95% of AWP to 85% of AWP and institutes an increase in drug administration codes effective January 1, 2004.
- **Phase 2:** CMS institutes a new drug pricing system based on the Average Sales (ASP) price of a drug with additional drug administration price increases effective January 1, 2005.
 - CMS's new system, the Average Sales Price (ASP), has been developed to reflect drug prices more accurately.
 - Standard payment rate for most Part B drugs will be set at 106% of the ASP.
 - The ASP Method will be applied to drugs supplied under the DME benefit, certain oral anti-cancer drugs and oral immunosuppressive drugs.

*Sources: 1) Federal Register/Vol. 69, No. 179/Thursday, September 16, 2004/Rules and Regs.
2) Private Payer News, Vol. 1, No. 9, October 2004*

Average Sales Price Determination

- **Quarterly Calculation of Manufacturer's ASP:**

CMS is requiring all drug manufacturers to submit to them, on a quarterly basis, data to determine the Average Sales Price for the drugs they sell.

A Manufacturer's Average Sales price is calculated by taking total US Sales for a drug and dividing it by number of units sold.

The following components are removed from the total sales calculation:

- volume discounts
- prompt pay discounts
- cash discounts
- free goods contingent on purchase requirement
- charge backs and rebates

Sources: 1) *Federal Register/Vol. 69, No. 179/Thursday, September 16, 2004/Rules and Regs.*

Drug Admin Pricing Increases

- The ASP pricing changes will have adverse affects on physician organizations' profitability in particular Oncology/Hematology physician organizations.
- MD fee schedule payments for oncologists and other specialties are increased to accurately pay MDs for the cost of administering drugs.

- Source: *Committee on Ways and Means, Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Chairman Bill Thomas 2/26/2004*

Drug Admin Fee Schedule Used for Analysis

Drug Administration - Fee Schedule

Code	Description	BCBSMA Fee	Conversion Factor	BCBSMA Fee	Conversion Factor
90471	Immunization admin	\$9.00		\$28.27	182%
90472	Immunization admin, each add	\$9.00		\$16.61	72%
90473	Immune admin oral/nasal	\$9.00		\$26.27	182%
90474	Immune admin oral/nasal addl	\$9.00		\$16.61	72%
90780	IV infusion therapy, 1 hour	\$54.07		\$127.12	135%
90781	IV infusion, additional hour	\$27.61		\$36.35	28%
90782	Injection, sc/im	\$5.53		\$28.81	385%
90783	Injection, ia	\$20.08		\$28.61	33%
90784	Injection, iv	\$23.23		\$53.61	131%
90788	Injection of antibiotic	\$6.00		\$23.59	293%
96400	Chemotherapy, sc/im	\$48.29		\$68.75	44%
96405	Intrasternal chemo admin	\$145.04		\$152.90	5%
96408	Chemotherapy, push technique	\$47.59		\$167.57	252%
96410	Chemotherapy, infusion method	\$76.28		\$235.37	213%
96412	Chemo, infuse method add-on	\$55.97		\$51.42	-8%
96414	Chemo, infuse method add-on	\$65.30		\$292.27	348%
96425	Chemotherapy, infusion method	\$69.58		\$262.01	262%
96520	Port pump refill & main	\$43.79		\$215.39	392%
96530	Syst pump refill & main	\$51.40		\$155.26	202%

Note: CMS Fees are an estimate of BCBSMA fee schedule pricing levels if the new CMS methodology was adopted. The estimate does not take into consideration the applicable BCBSMA conversion factor yet to be determined.

Impact to BCBSMA of New CMS Drug Pricing

- Drug Claims Data Set:
 - 6 months physician claims data.
 - Products: (HMO, POS, PPO, FEP, Indem, MCare Risk, MSP, Blue Card)
- Total Annualized Impact:
 - For the purposes of the CMS Drug Administration Pricing Analysis, drug codes 90471, 90472, 90473 and 90474 were maintained at Current BCBSMA Fee Levels (\$9.00)

	Current BCBSMA Fee Levels	Medicare Reform Fee Levels	Impact	Percent Change
Drug Supply Totals	\$38,171,174	\$28,058,946	-\$10,112,228	1.36
Drug Admin Totals	\$6,917,059	\$11,018,711	\$4,101,652	0.63
Total Costs	\$45,088,233	\$39,077,657	-\$6,010,576	

Drug Code Reform Impact Top 10 Total Dollar Impact by Type/Spec

Drug Code Impact Analysis by Type and Specialty

Analysis of the financial impact on each Type and Specialty of implementing Medicare ASP+6% pricing

	Pharmacy	Medical	Pharmacy	Medical	Pharmacy	Medical
	2009	2010	2009	2010	2009	2010
2059	Oncology/Hematology	\$31,457,860	\$17,897,637	\$13,660,714	\$31,457,860	\$17,897,637
2034	Urology	\$4,814,666	\$3,721,323	\$1,918,398	\$4,814,666	\$3,721,323
2011	Internal Medicine	\$8,461,321	\$5,777,537	\$4,432,738	\$8,461,321	\$5,777,537
2003	Allergy & Immunology	\$2,430,699	\$1,976,254	\$1,018,441	\$2,430,699	\$1,976,254
2042	Rheumatology	\$5,492,018	\$4,121,317	\$3,333,336	\$5,492,018	\$4,121,317
2007	Dermatology	\$1,259,017	\$657,366	\$420,195	\$1,259,017	\$657,366
2010	Gastroenterology	\$1,542,308	\$1,071,737	\$860,074	\$1,542,308	\$1,071,737
2006	Cardiovascular Disease	\$282,474	\$241,305	\$144,541	\$282,474	\$241,305
2020	Orthopedic Surgery	\$1,287,789	\$741,555	\$664,361	\$1,287,789	\$741,555
2039	Nephrology	\$297,316	\$231,206	\$179,374	\$297,316	\$231,206
	Top 10 Totals:	\$57,325,467	\$36,437,236	\$26,632,172	\$57,325,467	\$36,437,236
	All other Types and Specialties:	\$2,467,386	\$1,733,939	\$1,426,775	\$2,467,386	\$1,733,939
	Total Amounts:	\$59,792,854	\$38,171,174	\$28,058,946	\$59,792,854	\$38,171,174

Admin Code Reform Impact Top 10 Type/Spec

Drug Administration Code Analysis - Drug Administration Type and Specialty Impact Analysis

	Specialty	Diagnosis	Procedure	Medication	Other	Other	Other
2059	Oncology/Hematology	\$6,874,292	\$1,722,922	\$4,072,463	\$2,099,941	\$2,099,941	13.37%
2011	Internal Medicine	\$1,929,242	\$740,293	\$1,669,960	\$229,282	\$229,282	12.56%
2016	Obstetrics/Gynecology	\$183,022	\$46,623	\$201,080	\$45,341	\$45,341	4.12%
2042	Rheumatology	\$449,863	\$154,611	\$300,756	\$149,445	\$149,445	3.52%
2006	Family Practice	\$553,281	\$253,332	\$352,354	\$150,927	\$150,927	3.02%
2003	Allergy & Immunology	\$245,167	\$71,566	\$135,394	\$69,207	\$69,207	3.15%
2035	Pediatric	\$6,642,266	\$3,527,707	\$3,575,901	\$2,159,641	\$2,159,641	10.07%
2001	General Practice	\$71,099	\$40,146	\$83,917	\$37,771	\$37,771	1.63%
2034	Urology	\$125,440	\$71,371	\$111,362	\$14,078	\$14,078	1.06%
2010	Gastroenterology	\$113,500	\$40,863	\$80,172	\$39,308	\$39,308	1.62%
	Top 10 Totals:	\$17,187,163	\$6,669,433	\$10,583,358	\$3,690,491	\$3,690,491	8.98%
	All other Types and Specialties:	\$577,137	\$247,626	\$435,353	\$199,727	\$199,727	3.00%
	Total Analysis:	\$17,764,300	\$6,917,059	\$11,018,711	\$3,890,218	\$3,890,218	9.00%

Total Reform Type/Spec Impact

Drug and Administration Code Analysis - Total Type and Specialty Impact Analysis

	Specialty	Annual Charges	Drug and Admin. Fees	Medical Supplies	Other Charges	Charges Excluded	% of Charges
2059	Oncology/Hematology	\$38,332,152	\$19,620,558	\$17,733,177	\$1,978,417	\$38,332,152	31.63%
2034	Urology	\$4,940,107	\$3,792,694	\$2,029,760	\$1,118,653	\$4,940,107	4.03%
2003	Allergy & Immunology	\$2,675,866	\$2,047,820	\$1,153,835	\$898,165	\$2,675,866	2.18%
2042	Rheumatology	\$5,941,872	\$4,275,928	\$3,634,092	\$1,641,836	\$5,941,872	4.83%
2011	Internal Medicine	\$10,380,563	\$6,517,829	\$6,102,698	\$3,415,131	\$10,380,563	8.46%
2007	Dermatology	\$1,368,768	\$700,678	\$493,657	\$174,433	\$1,368,768	1.11%
2010	Gastroenterology	\$1,655,808	\$1,112,600	\$940,246	\$472,354	\$1,655,808	1.35%
2020	Orthopedic Surgery	\$1,288,251	\$741,835	\$665,577	\$380,849	\$1,288,251	1.05%
2006	Cardiovascular Disease	\$325,707	\$261,377	\$191,476	\$79,901	\$325,707	0.27%
2039	Nephrology	\$323,974	\$239,409	\$202,157	\$117,252	\$323,974	0.26%
	Top 10 Totals:	\$67,243,068	\$39,310,728	\$33,146,674	\$16,449,631	\$67,243,068	5.46%
	All other Types and Specialties:	\$10,314,086	\$5,777,505	\$5,930,983	\$3,478,359	\$10,314,086	0.84%
	Total Specialty	\$77,557,154	\$45,088,233	\$39,077,657	\$19,927,990	\$77,557,154	6.30%

Drug Reform Coding Impact

Top 10 Codes Based On Total Dollar Impact

Analysis of the financial impact of implementing Medicare ASP+6% pricing

Code	Description	Current Charges	Revised Charge	ASP	2004 Total Quantity	Allowed ASP+6%	2004 Total Dollars	2004 Total Dollars
J1563	IV immune globulin	\$4,313,568	\$2,966,332	\$75.90	\$38.02	\$1,529,012	\$1,679,926	\$1,679,926
J9217	Leuprolide acetate suspension	\$3,267,996	\$2,514,258	\$566.54	\$242.26	\$1,088,716	\$1,425,542	\$1,425,542
J1745	Infliximab injection	\$8,919,852	\$6,845,546	\$65.64	\$53.28	\$5,551,456	\$1,294,089	\$1,294,089
J9265	Paclitaxel injection	\$1,989,454	\$1,162,525	\$164.51	\$17.84	\$134,192	\$1,023,333	\$1,023,333
Q0136	Non esrd epoetin alpha inj	\$5,671,079	\$3,455,236	\$12.98	\$10.34	\$2,750,357	\$1,604,629	\$1,604,629
J9202	Goserelin acetate implant	\$1,246,349	\$1,037,128	\$427.47	\$216.10	\$533,335	\$1,603,791	\$1,603,791
J2505	Injection, pegfilgrastim 6mg	\$4,028,356	\$2,673,585	\$2,811.80	\$2,277.58	\$2,172,811	\$590,774	\$590,774
J2430	Pamidronate disodium /30 MG	\$679,231	\$484,947	\$269.29	\$57.63	\$105,117	\$1,829,880	\$1,829,880
J0880	Darbepoetin alfa injection	\$2,876,733	\$1,489,248	\$24.67	\$18.45	\$1,159,841	\$1,224,402	\$1,224,402
J9310	Rituximab cancer treatment	\$2,358,183	\$1,620,685	\$489.35	\$438.38	\$1,415,967	\$1,302,717	\$1,302,717
	Top 10 Codes:	\$35,350,800	\$24,249,490			\$16,440,806	\$18,608,684	\$18,608,684
	All other codes:	\$24,442,053	\$13,921,685			\$11,618,140	\$2,303,542	\$2,303,542
	Total Amount:	\$59,792,853	\$38,171,174			\$28,058,946	\$20,912,226	\$20,912,226

Option 1:

- Move to CMS ASP with changes in Admin Fees
 - Pros:
 - Administratively easy to maintain
 - Every provider is paid in the same way
 - Consistency among all product lines (Commercial, BC65 reimbursed using the same methodology)
 - Cons:
 - High impact to certain provider types (i.e., Oncology)
 - Resistance to changes by network
 - Potential shift to facility setting (Oncologists)
 - Uncertain future of CMS continuing with this payment methodology
 - Total Impact: -\$6,010,576

Option 2

- Move to a **Budget Neutral** CMS ASP Methodology without changes in Administration Fees
 - This option would include adopting the CMS ASP Drug Fee Methodology while applying a “multiplier” to the fees. This option would allow BCBSMA to adopt the CMS ASP Methodology without reducing the total payments for drugs on a network-wide basis.
- Pro:
 - Follow CMS’s standard drug methodology
 - Overall Budget Neutrality to BCBSMA
 - Source for pricing updates
- Con:
 - Although this methodology is budget neutral on a network-wide basis, some specialties may be adversely affected (i.e. – oncologists)
- Budget Neutral Drug Code Multiplier: 1.36

Option 3:

- Maintain current 95% of 2004 CMS AWP's
 - Pros:
 - Never Update
 - No major system changes
 - Cons:
 - Stagnant Drug Fees
 - Not following standard set by CMS
 - Total Impact: \$0

Option 4:

- Find drug vendor who can supply AWP's on a "J" Code Level.
 - Pros:
 - Can maintain current 95% of AWP methodology and level
 - Can be updated quarterly
 - Can set the percentage of AWP to whatever we find appropriate
 - Cons:
 - Does not follow CMS method
 - Drug Administration Fees will not increase

Next Steps

- Need decision/direction on physician drug reimbursement methodology
- Does BC65 have to follow CMS's drug payment methodology
- Timing – implementation date of change
- Notice to network

ASP +6% vs FS-16

Code	Description	Code Dosage	CY 2004 2nd Quarter ASP	FS-16	Eff Date	ASP + 6% vs	
			+ 6 %			FS-16	% diff
J7330	Cultured chondrocytes implnt	1dose	\$14,735.92	\$0.00	10/1/2002	\$14,735.92	100.0%
Q2014	Sermorelin acetate, 0.5 mg	0.5mg	\$782.11	\$15.78	1/1/2002	\$766.33	98.0%
Q0170	Promethazine HCl 25 mg oral	25mg	\$0.21	\$0.02	3/1/2004	\$0.19	90.5%
J7506	Prednisone oral	5mg	\$0.24	\$0.03	3/1/2004	\$0.21	87.5%
Q2008	Fomepizole, 15 mg	15mg	\$9.20	\$1.15	4/1/2003	\$8.05	87.5%
J0270	Alprostadil for injection	1.25mcg	\$1.69	\$0.34	3/1/2004	\$1.35	79.9%
J1230	Methadone injection	10mg	\$3.06	\$0.75	1/1/2002	\$2.31	75.5%
J3420	Vitamin b12 injection	1000mcg	\$0.50	\$0.17	3/1/2004	\$0.33	66.0%
J1815	Insulin Injection	5units	\$0.22	\$0.10	1/1/2003	\$0.12	54.5%
J0300	Amobarbital 125 MG inj	125mg	\$5.56	\$2.66	10/1/2003	\$2.90	52.2%
J2560	Phenobarbital sodium inj	120mg	\$3.21	\$1.61	3/1/2004	\$1.60	49.8%
J1000	Depo-estradiol cypionate inj	5mg	\$5.03	\$2.60	10/1/2004	\$2.43	48.3%
J2700	Oxacillin sodium injection	250mg	\$1.49	\$0.80	4/1/2003	\$0.69	46.3%
J3030	Sumatriptan succinate / 6 MG	6mg	\$47.80	\$26.56	10/1/2002	\$21.24	44.4%
Q2007	Ethanolamine oleate 100 mg	100mg	\$126.55	\$72.43	3/1/2004	\$54.12	42.8%
J2400	Chloroprocaine hcl injection	30ml	\$11.02	\$6.39	10/1/2002	\$4.63	42.0%
J2310	Inj naloxone hydrochloride	1mg	\$4.05	\$2.37	7/1/2003	\$1.68	41.5%
J0580	Penicillin g benzathine inj	2,4000,000units	\$64.55	\$39.56	7/1/2003	\$24.99	38.7%
J1080	Testosterone cypionate 200 MG	1cc_200mg	\$15.27	\$9.44	3/1/2004	\$5.83	38.2%
J0800	Corticotropin Injection	1-40units	\$148.80	\$92.93	3/1/2004	\$55.87	37.5%
Q2006	Digoxin immune fab (ovine)	1vial	\$605.63	\$380.00	3/1/2004	\$225.53	37.2%
J0570	Penicillin g benzathine inj	1,200,000units	\$29.77	\$19.78	7/1/2003	\$9.99	33.6%
J2930	Methylprednisolone injection	125mg	\$2.68	\$1.92	3/1/2004	\$0.76	28.4%
J9216	Interferon gamma 1-b inj	3millionunits	\$291.08	\$209.21	3/1/2004	\$81.87	28.1%
J9212	Interferon alfacon-1	1mcg	\$5.70	\$4.10	3/1/2004	\$1.60	28.1%
J3265	Injection torsemide 10 mg/ml	10mg	\$2.16	\$1.56	10/1/2003	\$0.60	27.8%
J2515	Pentobarbital sodium inj	50mg	\$1.78	\$1.32	10/1/2003	\$0.46	25.8%
J1610	Glucagon hydrochloride/1 MG	1mg	\$60.58	\$45.60	7/1/2003	\$14.98	24.7%
J1030	Methylprednisolone 40 MG inj	40mg	\$5.46	\$4.13	10/1/2003	\$1.33	24.4%
Q4076	Dopamine hcl, 40 mg	40mg	\$0.81	\$0.62	3/1/2004	\$0.19	23.5%
Q0171	Chlorpromazine HCl 10mg oral	10mg	\$0.09	\$0.07	10/1/2002	\$0.02	22.2%
J9320	Streptozocin injection	1gm	\$178.72	\$141.47	10/1/2003	\$37.25	20.8%
Q0167	Dronabinol 2.5mg oral	2.5mg	\$4.10	\$3.28	10/1/2002	\$0.82	20.0%
J2920	Methylprednisolone injection	40mg	\$1.90	\$1.58	3/1/2004	\$0.32	16.8%
J1642	Inj heparin sodium per 10 u	10units	\$0.06	\$0.05	3/1/2004	\$0.01	16.7%
J1830	Interferon beta-1b / .25 MG	0.25mg	\$80.57	\$67.22	3/1/2004	\$13.35	16.6%
J0745	Inj codeine phosphate /30 MG	30mg	\$0.55	\$0.46	3/1/2004	\$0.09	16.4%
J1040	Methylprednisolone 80 MG inj	80mg	\$9.74	\$8.27	10/1/2003	\$1.47	15.1%
J2795	Ropivacaine HCl injection	1mg	\$0.08	\$0.07	4/1/2003	\$0.01	12.5%
J3250	Trimethobenzamide hcl inj	200mg	\$1.59	\$1.40	3/1/2004	\$0.19	11.9%
Q0172	Chlorpromazine HCl 25mg oral	25mg	\$0.10	\$0.09	10/1/2002	\$0.01	10.0%
J9190	Fluorouracil injection	500mg	\$2.26	\$2.07	10/1/2003	\$0.19	8.4%
J2010	Uncomycin injection	1-300mg	\$3.46	\$3.18	10/1/2003	\$0.28	8.1%
J3320	Spectinomycin di-hcl inj	2gm	\$30.09	\$28.27	10/1/2003	\$1.82	6.0%
J2354	Octreotide inj, non-depot	25mcg	\$4.48	\$4.26	1/1/2004	\$0.22	4.9%
J2353	Octreotide injection, depot	1mg	\$83.38	\$79.66	10/1/2004	\$3.72	4.5%
J7525	Tacrolimus injection	5mg	\$122.70	\$118.80	4/1/2003	\$3.90	3.2%
J3240	Thyrotrophin Injection	0.9mg_1.1mg	\$638.12	\$618.19	10/1/2004	\$19.93	3.1%
J2210	Methylethergonovin maleate inj	0.2mg	\$4.21	\$4.11	3/1/2004	\$0.10	2.4%
J1720	Hydrocortisone sodium succ i	100mg	\$1.77	\$1.73	3/1/2004	\$0.04	2.3%
J0540	Penicillin g benzathine inj	1,200,000units	\$23.84	\$23.40	7/1/2003	\$0.54	2.3%
J1595	Injection glatiramer acetate	20mg	\$34.31	\$33.68	3/1/2004	\$0.63	1.8%
J0275	Alprostadil urethral suppos	1dose	\$20.63	\$20.31	3/1/2004	\$0.32	1.6%
J9050	Camus bischl nitro inj	200mg	\$137.96	\$136.17	7/1/2003	\$1.79	1.3%

ASP +6% vs FS-16

J9268	Pentostatin injection	10mg	\$1,853.45	\$1,837.72	3/1/2004	\$15.73	0.8%
J9300	Gemtuzumab ozogamicin	5mg	\$2,196.48	\$2,183.81	7/1/2003	\$12.67	0.6%
J7639	Domase alpha inhal sol u d	1mg	\$16.76	\$16.67	10/1/2002	\$0.09	0.5%
Q3025	IM Inj interferon beta 1-a	11mcg	\$85.79	\$85.63	10/1/2004	\$0.16	0.2%
J3480	Inj potassium chloride	2meq	\$0.08	\$0.08	4/1/2003	\$0.00	0.0%
J0735	Clonidine hydrochloride	1mg	\$54.96	\$55.16	1/1/2002	(\$0.20)	-0.4%
J1020	Methylprednisolone 20 MG Inj	20mg	\$2.67	\$2.68	10/1/2003	(\$0.01)	-0.4%
J1070	Testosterone cypionat 100 MG	100mg	\$4.90	\$4.95	10/1/2003	(\$0.05)	-1.0%
Q2017	Teniposide, 50 mg	50mg	\$254.63	\$257.46	7/1/2003	(\$2.83)	-1.1%
J7504	Lymphocyte immune globulin	250mg	\$275.33	\$278.70	10/1/2003	(\$3.37)	-1.2%
J3485	Zidovudine	10mg	\$0.99	\$1.01	3/1/2004	(\$0.02)	-2.0%
J1160	Digoxin Injection	0.5mg	\$1.74	\$1.78	3/1/2004	(\$0.04)	-2.3%
J0530	Penicillin g benzathine inj	600,00units	\$11.64	\$11.92	7/1/2003	(\$0.28)	-2.4%
J7342	Metabolically active tissue	1cm2	\$14.97	\$15.39	10/1/2004	(\$0.42)	-2.8%
J1835	Itraconazole injection	50mg	\$35.70	\$36.85	7/1/2003	(\$1.15)	-3.2%
J8700	Temozolomide	5mg	\$7.09	\$7.35	3/1/2004	(\$0.26)	-3.7%
J1440	Filgrastim 300 mcg injection	300mcg	\$170.51	\$177.15	3/1/2004	(\$6.64)	-3.9%
J3305	Inj trimetrexate glucuronate	25mg	\$137.00	\$142.50	10/1/2002	(\$5.50)	-4.0%
J7882	Tobramycin Inhalation sol	300mg	\$47.24	\$49.27	3/1/2004	(\$2.03)	-4.3%
J8510	Oral busulfan	2mg	\$1.99	\$2.08	3/1/2004	(\$0.09)	-4.5%
J0637	Caspofungin acetate	5mg	\$31.50	\$32.95	7/1/2003	(\$1.45)	-4.6%
J2324	Nesiritide	0.5mg	\$144.87	\$151.62	10/1/2003	(\$6.75)	-4.7%
J0725	Chorionic gonadotropin/1000u	1,000units	\$2.55	\$2.67	3/1/2004	(\$0.12)	-4.7%
J1327	Eptifibatide injection	5mg	\$12.25	\$12.83	4/1/2003	(\$0.58)	-4.7%
J1051	Medroxyprogesterone Inj	50mg	\$4.80	\$5.03	3/1/2004	(\$0.23)	-4.8%
J0702	Betamethasone acet&sod phosp	3mg	\$4.73	\$4.97	3/1/2004	(\$0.24)	-5.1%
J0585	Botulinum toxin a per unit	1unit	\$4.71	\$4.95	7/1/2003	(\$0.24)	-5.1%
Q2019	Basiliximab	20mg	\$1,461.34	\$1,538.42	10/1/2002	(\$77.08)	-5.3%
J2543	Piperacillin/tazobactam	1.125gm	\$4.63	\$4.88	3/1/2004	(\$0.25)	-5.4%
J9201	Gemcitabine HCl	200mg	\$115.26	\$121.57	10/1/2004	(\$6.31)	-5.5%
J7110	Dextran 75 infusion	500ml	\$13.44	\$14.21	10/1/2002	(\$0.77)	-5.7%
J7507	Tacrolimus oral per 1 MG	1mg	\$3.31	\$3.50	3/1/2004	(\$0.19)	-5.7%
J0205	Alglucerase injection	10units	\$39.22	\$41.50	3/1/2004	(\$2.28)	-5.8%
J7520	Sirolimus, oral	1mg	\$6.73	\$7.13	10/1/2002	(\$0.40)	-5.9%
Q2021	Lepirudin	50mg	\$135.07	\$143.17	7/1/2003	(\$8.10)	-6.0%
J1785	Injection imiglucerase /unit	1unit	\$3.91	\$4.15	3/1/2004	(\$0.24)	-6.1%
J0706	Caffeine citrate injection	5mg	\$3.23	\$3.43	3/1/2004	(\$0.20)	-6.2%
Q0179	Ondansetron HCl 8mg oral	8mg	\$28.64	\$30.42	3/1/2004	(\$1.78)	-6.2%
J0152	Adenosine injection	30mg	\$69.93	\$74.39	1/1/2004	(\$4.46)	-6.4%
J0895	Daferoxamine mesylate inj	500mg	\$14.62	\$15.63	7/1/2003	(\$1.01)	-6.9%
J9350	Topotecan	4mg	\$736.13	\$789.25	3/1/2004	(\$53.12)	-7.2%
J2770	Quinupristin/dalfopristin	500mg	\$106.32	\$114.58	10/1/2003	(\$8.26)	-7.8%
J0207	Amifostine	500mg	\$419.00	\$452.97	7/1/2003	(\$33.97)	-8.1%
J1410	Inj estrogen conjugate 25 MG	25mg	\$56.70	\$61.51	10/1/2003	(\$4.81)	-8.5%
J2300	Inj nalbuphine hydrochloride	10mg	\$1.39	\$1.51	7/1/2003	(\$0.12)	-8.6%
J9015	Aldesleukin/single use vial	per vial	\$670.39	\$734.46	7/1/2003	(\$64.07)	-9.6%
J0630	Calcitonin salmon injection	400units	\$35.02	\$38.41	10/1/2002	(\$3.39)	-9.7%
J9178	Inj, epirubicin hcl, 2 mg	2mg	\$25.19	\$27.64	1/1/2004	(\$2.45)	-9.7%
J0740	Cidofovir injection	375mg	\$768.71	\$843.60	7/1/2003	(\$74.89)	-9.7%
J1730	Diazoxide injection	300mg	\$112.03	\$122.95	4/1/2003	(\$10.92)	-9.7%
J1570	Ganciclovir sodium injection	500mg	\$32.10	\$35.24	3/1/2004	(\$3.14)	-9.8%
J1100	Dexamethasone sodium phos	1mg	\$0.10	\$0.11	3/1/2004	(\$0.01)	-10.0%
J2941	Somatropin injection	1mg	\$41.70	\$45.83	3/1/2004	(\$4.23)	-10.1%
J3487	Zoledronic acid	1mg	\$197.30	\$217.42	3/1/2004	(\$20.12)	-10.2%
J2355	Oprelvekin injection	5mg	\$242.68	\$267.87	3/1/2004	(\$25.19)	-10.4%
J1631	Haloperidol decanoate inj	50mg	\$8.25	\$9.12	10/1/2003	(\$0.87)	-10.5%
Q0169	Promethazine HCl 12.5mg oral	12.5mg	\$0.28	\$0.31	3/1/2004	(\$0.03)	-10.7%

ASP +6% vs FS-16

J1190	Dexrazoxane HCl injection	250mg	\$211.21	\$233.97	10/1/2003	(\$22.76)	-10.8%
J8520	Capecitabine, oral, 150 mg	150mg	\$3.24	\$3.59	3/1/2004	(\$0.35)	-10.8%
J3395	Verteporfin injection	15mg	\$1,322.06	\$1,465.99	10/1/2004	(\$143.93)	-10.9%
J0600	Edetate calcium disodium inj	1000mg	\$39.73	\$44.10	10/1/2003	(\$4.37)	-11.0%
J7505	Monoclonal antibodies	5mg	\$808.28	\$897.28	3/1/2004	(\$89.00)	-11.0%
J3465	Injection, voriconazole	10mg	\$4.54	\$5.04	1/1/2004	(\$0.50)	-11.0%
J9017	Arsenic trioxide	1mg	\$33.15	\$36.82	3/1/2004	(\$3.67)	-11.1%
J1441	Filgrastim 480 mcg injection	480mcg	\$269.23	\$299.29	3/1/2004	(\$30.06)	-11.2%
J8045	Carboplatin injection	50mg	\$134.23	\$149.29	10/1/2004	(\$15.06)	-11.2%
J2783	Rasburicase	0.6mg	\$106.04	\$117.96	1/1/2004	(\$11.92)	-11.2%
J8521	Capecitabine, oral, 500 mg	500mg	\$10.73	\$11.95	3/1/2004	(\$1.22)	-11.4%
J9355	Trastuzumab	10mg	\$52.04	\$58.13	10/1/2003	(\$6.09)	-11.7%
J0456	Azithromycin	500mg	\$22.67	\$25.39	3/1/2004	(\$2.72)	-12.0%
J7310	Ganciclovir long act implant	4.5mg	\$4,240.00	\$4,750.00	1/1/2002	(\$510.00)	-12.0%
J7517	Mycophenolate mofetil oral	250mg	\$2.54	\$2.85	3/1/2004	(\$0.31)	-12.2%
J7513	Dacizumab, parenteral	25mg	\$378.21	\$425.11	4/1/2003	(\$46.90)	-12.4%
J0295	Ampicillin sodium per 1.5 gm	1.5gm	\$6.60	\$7.42	4/1/2003	(\$0.82)	-12.4%
J1364	Erythro lactobionate /500 MG	500mg	\$3.12	\$3.51	10/1/2002	(\$0.39)	-12.5%
J2322	Nandrolone decanoate 200 MG	200mg	\$13.99	\$15.74	7/1/2003	(\$1.75)	-12.5%
J9001	Doxorubicin hcl liposome inj	10mg	\$349.64	\$393.48	7/1/2003	(\$43.84)	-12.5%
J7626	Budesonide inhalation sol	0.25-0.50mg	\$3.99	\$4.51	3/1/2004	(\$0.52)	-13.0%
J9213	Interferon alfa-2a inj	3millionunits	\$30.67	\$34.88	1/1/2002	(\$4.21)	-13.7%
J9600	Porfimer sodium	75mg	\$2,283.91	\$2,603.67	1/1/2002	(\$319.76)	-14.0%
J3486	Ziprasidone mesylate	10mg	\$18.22	\$20.79	1/1/2004	(\$2.57)	-14.1%
J9293	Miltoxantrone hydrochl / 5 MG	5mg	\$314.53	\$359.35	7/1/2003	(\$44.82)	-14.2%
J9010	Alemtuzumab injection	10mg	\$511.50	\$584.53	3/1/2004	(\$73.03)	-14.3%
Q4077	Treprostinil, 1 mg	1mg	\$54.02	\$61.75	3/1/2004	(\$7.73)	-14.3%
J9151	Danorubicin citrate liposom	10mg	\$56.51	\$64.60	1/1/2002	(\$8.09)	-14.3%
J2940	Somatrein injection	1mg	\$39.84	\$45.56	10/1/2002	(\$5.72)	-14.4%
J1950	Leuprolide acetate /3.75 MG	3.75mg	\$443.33	\$507.18	3/1/2004	(\$63.85)	-14.4%
J9310	Rituximab cancer treatment	100mg	\$438.38	\$501.76	10/1/2004	(\$63.38)	-14.5%
J1335	Ertapenem injection	500mg	\$20.74	\$23.74	1/1/2004	(\$3.00)	-14.5%
J8245	Inj melphalan hydrochl 50 MG	50mg	\$366.71	\$420.10	7/1/2003	(\$53.39)	-14.6%
J1980	Hyoscyamine sulfate inj	0.25mg	\$7.45	\$8.56	7/1/2003	(\$1.11)	-14.9%
J0587	Botulinum toxin type B	100units	\$7.64	\$8.79	1/1/2002	(\$1.15)	-15.1%
J7197	Antithrombin III injection	1l.U.	\$1.46	\$1.68	3/1/2004	(\$0.22)	-15.1%
J0720	Chloramphenicol sodium injec	1gm	\$8.27	\$7.22	7/1/2003	(\$0.95)	-15.2%
J9395	Injection, Fulvestrant	25mg	\$79.11	\$91.16	7/25/2004	(\$12.05)	-15.2%
J9230	Mechlorethamine hcl inj	10mg	\$10.41	\$12.01	10/1/2002	(\$1.60)	-15.4%
J0515	Inj benztropine mesylate	1mg	\$3.38	\$3.90	10/1/2002	(\$0.52)	-15.4%
J9020	Asparaginase injection	10,000units	\$54.20	\$62.61	10/1/2002	(\$8.41)	-15.5%
J1205	Chlorothalazide sodium inj	500mg	\$9.08	\$10.49	4/1/2003	(\$1.41)	-15.5%
J9214	Interferon alfa-2b inj	1millionunits	\$12.85	\$14.88	10/1/2003	(\$2.03)	-15.8%
J9263	Oxaliplatin	0.5mg	\$8.16	\$9.45	3/1/2004	(\$1.29)	-15.8%
J9170	Docetaxel	20mg	\$290.78	\$336.86	3/1/2004	(\$46.08)	-15.8%
J9120	Dactinomycin actinomycin d	0.5mg	\$11.97	\$13.87	10/1/2002	(\$1.90)	-15.9%
J9206	Irinotecan injection	20mg	\$125.41	\$145.56	10/1/2004	(\$20.15)	-16.1%
J3130	Testosterone enanthate inj	1-200mg	\$15.47	\$17.96	10/1/2003	(\$2.49)	-16.1%
J3120	Testosterone enanthate Inj	100mg	\$7.73	\$8.98	10/1/2003	(\$1.25)	-16.2%
J0130	Abciximab injection	10mg	\$440.53	\$513.02	1/1/2002	(\$72.49)	-16.5%
J2995	Inj streptokinase /250000 IU	250,000U.	\$76.32	\$89.06	7/1/2003	(\$12.74)	-16.7%
J1650	Inj enoxaparin sodium	10mg	\$5.22	\$6.10	3/1/2004	(\$0.88)	-16.9%
J0692	Cefepime HCl for injection	500mg	\$6.90	\$8.13	10/1/2002	(\$1.23)	-17.8%
Q0168	Dronabinol 5mg oral	5mg	\$7.51	\$8.90	3/1/2004	(\$1.39)	-18.5%
J0216	Alefacept	0.5mg	\$26.57	\$31.51	1/1/2004	(\$4.94)	-18.6%
J9211	Idarubicin hcl injection	5mg	\$353.15	\$419.94	7/1/2003	(\$66.78)	-18.9%
J1742	Ibutilide fumarate injection	1mg	\$210.89	\$251.35	10/1/2003	(\$40.46)	-19.2%

ASP +6% vs FS-16

J0476	Baclofen intrathecal trial	50mcg	\$66.72	\$79.80	1/1/2002	(\$13.08)	-19.6%
J0715	Ceftriaxone sodium / 500 MG	500mg	\$4.14	\$4.96	4/1/2003	(\$0.82)	-19.8%
J0475	Baclofen 10 MG injection	10mg	\$179.19	\$215.18	3/1/2004	(\$35.99)	-20.1%
J0150	Injection adenosine 6 MG	6mg	\$32.30	\$38.89	7/1/2003	(\$6.59)	-20.4%
Q2009	Fosphenytoin, 50 mg	50mg	\$5.04	\$6.08	3/1/2004	(\$1.04)	-20.6%
J2320	Nandrolone decanoate 50 MG	50mg	\$3.16	\$3.83	3/1/2004	(\$0.67)	-21.2%
J1450	Fluconazole	200mg	\$79.08	\$95.92	7/1/2003	(\$16.84)	-21.3%
J2997	Alteplase recombinant	1mg	\$30.22	\$36.69	3/1/2004	(\$6.47)	-21.4%
J3245	Tirofiban hydrochloride	12.5mg	\$386.27	\$471.39	7/1/2003	(\$85.12)	-22.0%
J7320	Hylan G-F 20 Injection	16mg	\$190.74	\$233.53	10/1/2004	(\$42.79)	-22.4%
J7317	Sodium hyaluronate injection	20-25mg	\$112.89	\$138.71	10/1/2003	(\$25.82)	-22.9%
J9160	Denileukin difitox, 300 mcg	300mcg	\$1,082.88	\$1,330.95	10/1/2003	(\$248.09)	-22.9%
J2605	Injection, pegfilgrastim 6mg	6mg	\$2,277.58	\$2,802.50	1/1/2004	(\$524.92)	-23.0%
J2597	Inf desmopressin acetate	1mcg	\$2.80	\$3.45	7/1/2003	(\$0.65)	-23.2%
J1745	Infliximab Injection	10mg	\$53.28	\$65.70	1/1/2002	(\$12.42)	-23.3%
J3301	Triamcinolone acetonide inj	10mg	\$1.28	\$1.60	10/1/2003	(\$0.31)	-24.0%
J7511	Antithymocyte globulin rabbit	25mg	\$288.12	\$357.58	10/1/2003	(\$69.46)	-24.1%
J0592	Buprenorphine hydrochloride	0.1mg	\$0.82	\$1.02	3/1/2004	(\$0.20)	-24.4%
J2501	Paricalcitol	1mcg	\$4.02	\$5.02	4/1/2003	(\$1.00)	-24.9%
J9065	Inf cladribine per 1 MG	1mg	\$41.06	\$51.30	10/1/2003	(\$10.24)	-24.9%
J7516	Cyclosporin parenteral 250mg	250mg	\$20.02	\$25.08	1/1/2002	(\$5.06)	-25.3%
Q0136	Non esrd epoetin alpha inj	1,000units	\$10.34	\$12.99	3/1/2004	(\$2.65)	-25.6%
J7515	Cyclosporine oral 25 mg	25mg	\$1.04	\$1.31	1/1/2002	(\$0.27)	-26.0%
J7195	Factor IX recombinant	11.U.	\$0.84	\$1.06	3/1/2004	(\$0.22)	-26.2%
J3365	Epoetin 250,000 IU inj	250,000IU.	\$401.95	\$511.50	4/1/2003	(\$109.55)	-27.3%
J2510	Penicillin g procaine inj	600,000units	\$7.49	\$9.60	10/1/2003	(\$2.11)	-28.2%
J7502	Cyclosporine oral 100 mg	100mg	\$4.07	\$5.22	1/1/2002	(\$1.15)	-28.3%
J3360	Diazepam injection	5mg	\$0.67	\$0.86	10/1/2003	(\$0.19)	-28.4%
J0880	Darbepoetin alfa injection	5mcg	\$18.45	\$23.69	1/1/2003	(\$5.24)	-28.4%
Q0137	Darbepoetin alfa, non-esrd	1mcg	\$3.69	\$4.74	1/1/2004	(\$1.05)	-28.5%
Q4054	Darbepoetin alfa, esrd use	1mcg	\$3.69	\$4.74	3/1/2004	(\$1.05)	-28.5%
J7194	Factor ix complex	11.U.	\$0.35	\$0.45	3/1/2004	(\$0.10)	-28.6%
J1652	Fondaparinux sodium	0.5mg	\$6.39	\$8.27	1/1/2003	(\$1.88)	-29.4%
J7501	Azathioprine parenteral	100mg	\$48.06	\$59.84	10/1/2002	(\$13.78)	-29.9%
J9185	Fludarabine phosphate inj	50mg	\$273.54	\$356.07	10/1/2003	(\$82.53)	-30.2%
J1165	Phenytoin sodium injection	50mg	\$0.66	\$0.86	4/1/2003	(\$0.20)	-30.3%
J0780	Prochlorperazine injection	10mg	\$3.20	\$4.18	10/1/2003	(\$0.98)	-30.6%
J1817	Insulin for insulin pump use	50units	\$2.15	\$2.81	3/15/2004	(\$0.66)	-30.7%
J1455	Foscamet sodium injection	1000mg	\$9.98	\$13.08	3/1/2004	(\$3.10)	-31.1%
J2550	Promethazine hcl Injection	1-50mg	\$2.17	\$2.85	7/1/2003	(\$0.68)	-31.3%
J2410	Oxymorphone hcl injection	1mg	\$2.22	\$2.95	7/1/2003	(\$0.73)	-32.9%
J3100	Tenecteplase injection	50mg	\$2,017.07	\$2,690.88	10/1/2003	(\$673.81)	-33.4%
J9031	Bcg live intravesical vac	perinstallation	\$119.89	\$160.13	7/1/2003	(\$40.24)	-33.6%
J0210	Methyldopa hcl injection	250mg	\$8.87	\$11.88	4/1/2003	(\$3.01)	-33.9%
J1110	Inf dihydroergotamine mesylt	1mg	\$30.03	\$40.28	7/1/2003	(\$10.25)	-34.1%
J2321	Nandrolone decanoate 100 MG	100mg	\$5.20	\$6.98	3/1/2004	(\$1.78)	-34.2%
J9140	Dacarbazine 200 MG inj	200mg	\$16.08	\$21.76	3/1/2004	(\$5.68)	-35.3%
J2185	Meropenem	100mg	\$3.63	\$4.92	1/1/2004	(\$1.29)	-35.5%
J2590	Oxytocin injection	10units	\$0.93	\$1.28	3/1/2004	(\$0.35)	-37.6%
J0743	Cilastatin sodium injection	250mg	\$11.38	\$15.87	10/1/2002	(\$4.49)	-39.5%
J0770	Colistimethate sodium inj	150mg	\$38.62	\$54.15	10/1/2002	(\$15.53)	-40.2%
Q0166	Granisetron HCl 1 mg oral	1mg	\$31.86	\$44.69	10/1/2002	(\$12.83)	-40.3%
J7308	Aminolevulinic acid hcl top	354mg	\$88.76	\$124.58	7/25/2004	(\$35.82)	-40.4%
J9390	Vinorelbine tartrate/10 mg	20mg	\$60.46	\$85.15	3/1/2004	(\$24.69)	-40.8%
J2690	Procainamide hcl injection	1gm	\$0.98	\$1.39	3/1/2004	(\$0.41)	-41.8%
J2760	Phentolamine mesylate inj	5mg	\$22.50	\$31.92	10/1/2003	(\$9.42)	-41.9%
J0460	Atropine sulfate injection	0.3mg	\$0.57	\$0.82	3/1/2004	(\$0.25)	-43.9%

ASP +6% vs FS-16

J7340	Metabolic active D/E tissue	1cm2	\$20.19	\$29.30	4/1/2003	(\$9.11)	-45.1%
Q0180	Dolasetron mesylate oral	100mg	\$49.87	\$72.43	10/1/2002	(\$22.56)	-45.2%
J3370	Vancomycin hcl Injection	500mg	\$1.97	\$2.88	3/1/2004	(\$0.91)	-46.2%
J7100	Dextran 40 infusion	500ml	\$17.08	\$25.11	4/1/2003	(\$8.03)	-47.0%
Q2022	VonWillebrandFactorCmplxperIU	11.U.	\$0.72	\$1.06	3/1/2004	(\$0.34)	-47.2%
J0694	Cefoxitin sodium injection	1gm	\$7.25	\$10.69	4/1/2003	(\$3.44)	-47.4%
J2993	Retepase injection	18.1mg	\$881.81	\$1,306.25	3/1/2004	(\$424.44)	-48.1%
J1260	Dolasetron mesylate	10mg	\$10.38	\$15.48	3/1/2004	(\$5.10)	-49.1%
J0697	Sterile cefuroxime injection	750mg	\$4.28	\$6.42	1/1/2002	(\$2.14)	-50.0%
J1326	Epoprostenol Injection	0.5mg	\$12.03	\$18.06	10/1/2001	(\$6.03)	-50.1%
J2780	Ranitidine hydrochloride inj	25mg	\$0.95	\$1.44	3/1/2004	(\$0.49)	-51.6%
J0256	Alpha 1 proteinase inhibitor	10mg	\$1.73	\$2.66	7/1/2003	(\$0.93)	-53.8%
J2730	Prafoxime chloride inj	1gm	\$66.77	\$102.96	1/1/2002	(\$36.19)	-54.2%
J7621	(Levo)albuterol/lpra-bromide	5mg	\$2.45	\$3.80	1/1/2004	(\$1.35)	-55.1%
J2020	Linezolid Injection	200mg	\$23.65	\$36.80	10/1/2003	(\$13.15)	-55.6%
J7192	Factor viii recombinant	11.U.	\$0.92	\$1.44	3/1/2004	(\$0.52)	-56.5%
J2820	Sargramostim Injection	50mcg	\$17.39	\$27.35	3/1/2004	(\$9.96)	-57.3%
J1750	Iron dextran	50mg	\$11.22	\$17.91	1/1/2002	(\$6.69)	-59.6%
J2405	Ondansetron hcl injection	1mg	\$3.80	\$6.23	3/1/2004	(\$2.43)	-63.9%
J1120	Acetazolamid sodium injectio	50mg	\$12.46	\$20.52	10/1/2003	(\$8.06)	-64.7%
J3430	Vitamin k phytionadione inj	1mg	\$1.34	\$2.21	3/1/2004	(\$0.87)	-64.9%
J0289	Amphotericin b liposome inj	10mg	\$21.69	\$35.80	4/1/2003	(\$14.11)	-65.1%
J8530	Cyclophosphamide oral 25 MG	25mg	\$1.18	\$1.96	3/1/2004	(\$0.78)	-66.1%
J1756	Iron sucrose injection	1mg	\$0.39	\$0.65	3/1/2004	(\$0.26)	-66.7%
J2370	Phenylephrine hcl injection	1ml	\$0.76	\$1.28	10/1/2003	(\$0.52)	-68.4%
J2792	Rho(D) immune globulin h, sd	100IU	\$12.12	\$20.55	1/1/2002	(\$8.43)	-69.6%
J7198	Anti-inhibitor	11.U.	\$0.93	\$1.59	3/1/2004	(\$0.66)	-71.0%
J7193	Factor IX non-recombinant	11.U.	\$0.73	\$1.25	3/1/2004	(\$0.52)	-71.2%
J0288	Ampho b cholesteryl sulfate	10mg	\$8.87	\$15.20	1/1/2003	(\$6.33)	-71.4%
J0760	Colchicine Injection	1mg	\$4.10	\$7.07	1/1/2002	(\$2.97)	-72.4%
J2916	Na ferric gluconate complex	12.5mg	\$4.71	\$8.17	1/1/2003	(\$3.46)	-73.5%
J1644	Inj heparin sodium per 1000u	1000units	\$0.23	\$0.40	10/1/2003	(\$0.17)	-73.9%
J2675	Inj progesterone per 50 MG	50mg	\$2.02	\$3.55	3/1/2004	(\$1.53)	-75.7%
J9250	Methotrexate sodium inj	5mg	\$0.22	\$0.39	7/1/2003	(\$0.17)	-77.3%
J1200	Diphenhydramine hcl injectio	1-50mg	\$0.90	\$1.60	3/1/2004	(\$0.70)	-77.8%
J1250	Inj dobutamine HCL/250 mg	250mg	\$2.65	\$4.74	7/1/2003	(\$2.09)	-78.9%
Q0187	Factor viia recombinant	1.2mg	\$1,047.58	\$1,879.32	3/1/2004	(\$831.74)	-79.4%
J1800	Propranolol Injection	1mg	\$5.21	\$9.45	3/1/2004	(\$4.24)	-81.4%
J1645	Dalteparin sodium	2500I.U.	\$8.57	\$15.69	10/1/2003	(\$7.12)	-83.1%
J8560	Etoposide oral 50 MG	50mg	\$24.59	\$45.26	3/1/2004	(\$20.67)	-84.1%
J7618	Albuterol inh sol con	1mg	\$0.07	\$0.13	3/1/2004	(\$0.06)	-85.7%
J3260	Tobramycin sulfate injection	80mg	\$2.40	\$4.46	7/1/2003	(\$2.06)	-85.8%
J1955	Inj levocarnitine per 1 gm	1gm	\$18.35	\$34.20	1/1/2002	(\$15.85)	-86.4%
J9200	Floxuridine Injection	500mg	\$72.67	\$136.80	10/1/2003	(\$64.13)	-88.2%
J1180	Dyphylline Injection	500mg	\$4.77	\$9.01	3/1/2004	(\$4.24)	-88.9%
J9060	Cisplatin 10 MG injection	10mg	\$8.01	\$15.15	3/1/2004	(\$7.14)	-89.1%
J9062	Cisplatin 50 MG injection	50mg	\$40.03	\$75.76	3/1/2004	(\$35.73)	-89.3%
J0713	Inj ceftazidime per 500 mg	500mg	\$3.56	\$6.75	4/1/2003	(\$3.19)	-89.6%
J3105	Terbutaline sulfate Inj	1mg	\$15.31	\$29.39	4/1/2003	(\$14.08)	-92.0%
J0696	Ceftriaxone sodium injection	250mg	\$7.73	\$14.92	10/1/2002	(\$7.19)	-93.0%
J9000	Doxorubicin hcl 10 MG vi chemo	10mg	\$4.72	\$9.12	3/1/2004	(\$4.40)	-93.2%
J2788	Rho d immune globulin 50 mcg	50mcg	\$26.50	\$51.21	3/1/2004	(\$24.71)	-93.2%
J1563	IV immune globulin	1g	\$38.02	\$73.76	3/1/2004	(\$35.74)	-94.0%
J9202	Goserelin acetate implant	3.6mg	\$216.10	\$420.23	3/1/2004	(\$204.13)	-94.5%
J9110	Cytarabine hcl 500 MG inj	500mg	\$4.39	\$8.55	10/1/2003	(\$4.16)	-94.8%
J9340	Thiotepa Injection	15mg	\$47.90	\$93.58	3/1/2004	(\$45.68)	-95.4%
J3230	Chlorpromazine hcl injection	50mg	\$2.25	\$4.40	7/1/2003	(\$2.15)	-95.6%

ASP +6% vs FS-16

J0280	Aminophyllin 250 MG Inj	250mg	\$0.53	\$1.05	10/1/2002	(\$0.52)	-98.1%
J1270	Injection, doxercalciferol	1mcg	\$2.76	\$5.50	10/1/2003	(\$2.74)	-99.3%
J0360	Hydralazine hcl injection	20mg	\$7.84	\$16.03	3/1/2004	(\$8.19)	-104.5%
J0500	Dicyclomine Injection	20mg	\$8.27	\$17.06	10/1/2003	(\$8.79)	-106.3%
J1630	Haloperidol injection	5mg	\$3.30	\$6.83	10/1/2003	(\$3.53)	-107.0%
J2060	Lorazepam injection	2mg	\$1.51	\$3.14	4/1/2003	(\$1.63)	-107.9%
J1790	Droperidol Injection	5mg	\$1.34	\$2.80	3/1/2004	(\$1.46)	-109.0%
J0550	Penicillin g benzathine inj	2,400,000units	\$23.88	\$50.12	7/1/2003	(\$26.24)	-109.9%
J9209	Mesna injection	200mg	\$16.67	\$35.15	3/1/2004	(\$18.48)	-110.9%
J0330	Succinylcholine chloride inj	20mg	\$0.09	\$0.19	3/1/2004	(\$0.10)	-111.1%
J9260	Methotrexate sodium inj	50mg	\$2.21	\$4.75	7/1/2003	(\$2.54)	-114.9%
J9090	Cyclophosphamide 500 MG inj	500mg	\$10.63	\$22.86	10/1/2003	(\$12.23)	-115.1%
J7190	Factor viii	11.U.	\$0.45	\$0.98	3/1/2004	(\$0.53)	-117.8%
J9091	Cyclophosphamide 1.0 grm inj	1gm	\$20.98	\$45.73	10/1/2003	(\$24.75)	-118.0%
J9291	Mitomycin 40 MG Inj	40mg	\$128.60	\$285.00	10/1/2003	(\$156.40)	-121.6%
Q0163	Diphenhydramine HCl 50mg	50mg	\$0.04	\$0.09	3/1/2004	(\$0.05)	-125.0%
J9092	Cyclophosphamide 2.0 grm inj	2gm	\$40.54	\$91.45	10/1/2003	(\$50.91)	-125.6%
J9218	Leuprolide acetate Injection	1mg	\$11.47	\$26.00	3/1/2004	(\$14.53)	-126.7%
J3475	Inj magnesium sulfate	500mg	\$0.10	\$0.23	3/1/2004	(\$0.13)	-130.0%
J9217	Leuprolide acetate suspnslon	7.5mg	\$242.26	\$559.47	3/1/2004	(\$317.21)	-130.9%
J9097	Cyclophosphamide lyophilized	2gm	\$40.54	\$93.83	3/1/2004	(\$53.29)	-131.5%
J3315	Triptorelin pamoate	3.75mg	\$169.73	\$398.62	10/1/2003	(\$228.89)	-134.8%
J1940	Furosemide injection	20mg	\$0.40	\$0.98	10/1/2003	(\$0.58)	-145.0%
J9040	Bleomycin sulfate injection	15units	\$68.56	\$168.33	3/1/2004	(\$99.77)	-145.5%
J9219	Leuprolide acetate implant	65mg	\$2,197.36	\$5,399.80	1/1/2002	(\$3,202.44)	-145.7%
J0595	Butorphanol tartrate 1 mg	1mg	\$1.75	\$4.40	1/1/2004	(\$2.65)	-151.4%
J1655	Tinzaparin sodium injection	1000I.U.	\$1.52	\$3.83	10/1/2003	(\$2.31)	-152.0%
J7608	Acetylcysteine inh sol u d	1gm	\$2.36	\$5.95	3/15/2004	(\$3.59)	-152.1%
J0698	Cefotaxime sodium Injection	1gm	\$3.76	\$9.51	3/1/2004	(\$5.75)	-152.9%
J1626	Granisetron HCl Injection	100mcg	\$6.84	\$17.45	3/1/2004	(\$10.61)	-155.1%
Q0175	Perphenazine 4mg oral	4mg	\$0.22	\$0.57	10/1/2002	(\$0.35)	-159.1%
J9181	Etoposide 10 MG inj	10mg	\$0.65	\$1.71	10/1/2003	(\$1.06)	-163.1%
J0840	Leucovorin calcium injection	50mg	\$1.27	\$3.35	3/1/2004	(\$2.08)	-163.8%
J9182	Etoposide 100 MG inj	100mg	\$6.47	\$17.10	10/1/2003	(\$10.63)	-164.3%
J1590	Gatifloxacin injection	10mg	\$0.34	\$0.90	3/1/2004	(\$0.56)	-164.7%
J7070	D5w infusion	1000cc	\$4.12	\$10.93	3/1/2004	(\$6.81)	-165.3%
J0610	Calcium gluconate injection	10ml	\$0.38	\$1.01	3/1/2004	(\$0.63)	-165.8%
Q0183	Nonmetabolic active tissue	1cm2	\$5.73	\$15.40	7/1/2003	(\$9.67)	-168.8%
J9280	Mitomycin 5 MG inj	5mg	\$23.63	\$63.84	10/1/2003	(\$40.21)	-170.2%
J0636	Inj calcitriol per 0.1 mcg	0.1mcg	\$0.50	\$1.38	4/1/2003	(\$0.88)	-176.0%
J9150	Dauorubicin	10mg	\$28.35	\$74.23	10/1/2003	(\$47.88)	-181.7%
J1956	Levofloxacin injection	250mg	\$7.30	\$20.81	7/1/2003	(\$13.51)	-185.1%
J9208	Ifosfomide injection	1gm	\$51.93	\$150.38	4/1/2003	(\$98.45)	-189.6%
J1245	Dipyridamole injection	10mg	\$1.96	\$5.70	10/1/2003	(\$3.74)	-190.8%
J2912	Sodium chloride injection	2ml	\$0.16	\$0.50	3/1/2004	(\$0.34)	-212.5%
J9290	Mitomycin 20 MG inj	20mg	\$68.35	\$207.48	10/1/2003	(\$141.13)	-212.7%
J3010	Fentanyl citrate Injection	0.1mg	\$0.28	\$0.93	7/1/2003	(\$0.65)	-232.1%
J1580	Garamycin gentamicin inj	80mg	\$0.51	\$1.90	10/1/2003	(\$1.39)	-272.5%
J0690	Cefazolin sodium injection	500mg	\$0.60	\$2.25	10/1/2003	(\$1.65)	-275.0%
J0170	Adrenalin epinephrin inject	1ml	\$0.62	\$2.35	10/1/2003	(\$1.73)	-279.0%
J7050	Normal saline solution infus	250cc	\$0.64	\$2.48	3/1/2004	(\$1.84)	-287.5%
J2765	Metoclopramide hcl injection	10mg	\$0.47	\$1.87	3/1/2004	(\$1.40)	-297.9%
Q0176	Perphenazine 8mg oral	8mg	\$0.23	\$0.93	3/1/2004	(\$0.70)	-304.3%
Q0178	Hydroxyzine pamoate 50mg	50mg	\$0.07	\$0.30	3/1/2004	(\$0.23)	-328.6%
J7060	5% dextrose/water	1unit_500ml	\$2.04	\$9.05	3/1/2004	(\$7.01)	-343.6%
J2430	Pamidronate disodium /30 MG	30mg	\$57.83	\$265.87	7/1/2003	(\$208.24)	-361.3%
J2250	Inj midazolam hydrochloride	1mg	\$0.27	\$1.28	10/1/2003	(\$1.01)	-374.1%

ASP +6% vs FS-16

J7669	Metaproterenol inh sol u d	10mg	\$0.28	\$1.24	3/15/2004	(\$0.98)	-376.9%
J2680	Fluphenazine decanoate 25 MG	25mg	\$1.83	\$8.98	3/1/2004	(\$7.13)	-389.6%
J2440	Papaverin hcl Injection	60mg	\$0.68	\$3.33	3/1/2004	(\$2.65)	-389.7%
J7509	Methylprednisolone oral	4mg	\$0.10	\$0.49	3/1/2004	(\$0.39)	-390.0%
J9100	Cytarabine hcl 100 MG inj	100mg	\$1.65	\$8.19	3/1/2004	(\$6.54)	-396.4%
J9360	Vinblastine sulfate inj	1mg	\$0.61	\$3.14	3/1/2004	(\$2.53)	-414.8%
J7500	Azathioprine oral 50mg	50mg	\$0.22	\$1.24	3/1/2004	(\$1.02)	-463.6%
J2260	Inj milrinone lactate / 5 MG	5mg	\$9.11	\$51.58	7/1/2002	(\$42.47)	-466.2%
Q2002	Elliotts b solution per ml	1ml	\$2.60	\$15.00	3/1/2004	(\$12.40)	-476.9%
J7631	Cromolyn sodium inh sol u d	10mg	\$0.06	\$0.35	3/1/2004	(\$0.29)	-483.3%
J2150	Mannitol injection	50ml	\$0.65	\$3.27	10/1/2003	(\$2.72)	-494.5%
J9370	Vincristine sulfate 1 MG inj	1mg	\$5.00	\$33.98	4/1/2003	(\$28.98)	-579.6%
J9375	Vincristine sulfate 2 MG inj	2mg	\$10.00	\$67.96	7/1/2003	(\$57.96)	-579.6%
J9380	Vincristine sulfate 5 MG inj	5mg	\$24.99	\$169.91	3/1/2004	(\$144.92)	-579.9%
J7644	Ipratropium brom inh sol u d	1mg	\$0.46	\$3.15	3/1/2004	(\$2.69)	-584.8%
Q0177	Hydroxyzine pamoate 25mg	25mg	\$0.06	\$0.42	3/1/2004	(\$0.36)	-600.0%
J3364	Urokinase 5000 IU injection	5000U.	\$8.04	\$56.61	3/1/2004	(\$48.57)	-604.1%
J7051	Sterile saline/water	1-5cc	\$0.09	\$0.76	10/1/2003	(\$0.67)	-744.4%
J7619	Albuterol inh sol u d	1mg	\$0.05	\$0.43	3/1/2004	(\$0.38)	-760.0%
J9265	Paclitaxel injection	30mg	\$17.84	\$154.55	3/1/2004	(\$136.71)	-766.3%
J7040	Normal saline solution infus	1unit_500ml	\$0.63	\$6.30	3/1/2004	(\$5.67)	-900.0%
J0583	Bivalirudin	1mg	\$0.14	\$1.60	1/1/2004	(\$1.46)	-1042.9%
J0282	Amiodarone HCl	30mg	\$0.53	\$6.16	3/1/2004	(\$5.63)	-1062.3%
J3410	Hydroxyzine hcl injection	25mg	\$0.10	\$1.20	3/1/2004	(\$1.10)	-1100.0%
J8810	Methotrexate oral 2.5 MG	2.5mg	\$0.23	\$2.92	3/1/2004	(\$2.69)	-1169.6%
J7120	Ringers lactate infusion	1000cc	\$0.87	\$12.44	3/1/2004	(\$11.57)	-1329.9%
J7030	Normal saline solution infus	1000cc	\$0.67	\$9.93	3/1/2004	(\$9.26)	-1382.1%
Q4075	Acyclovir, 5 mg	5mg	\$0.03	\$0.47	3/1/2004	(\$0.44)	-1466.7%
J2710	Neostigmine methylsulfate inj	0.5mg	\$0.04	\$0.66	3/1/2004	(\$0.62)	-1550.0%
Q0165	Prochlorperazine maleate 10mg	10mg	\$0.05	\$0.86	3/1/2004	(\$0.81)	-1620.0%
Q0164	Prochlorperazine maleate 5mg	5mg	\$0.03	\$0.57	3/1/2004	(\$0.54)	-1800.0%
J7042	5% dextrose/normal saline	1unit_500ml	\$0.41	\$9.44	10/1/2002	(\$9.03)	-2202.4%
J2810	Inj theophylline per 40 MG	40mg	\$0.43	\$10.04	1/1/1999	(\$9.61)	-2234.9%
J2001	Lidocaine injection	10mg	\$0.02	\$0.98	1/1/2004	(\$0.96)	-4800.0%

Note: The Medicare payments effective January 1, 2005 will be based on CY 2004 3rd Quarter ASP data not yet available.

RVU04 x GPCI04 x CF04

	05	04		
W	1.306	1.041	CF	41.811
P	1.284	1.239		
M	0.823	0.803		

	05	04	05	04	05	04	05	04
	W	P	M	Total	W	P	M	Total
90471	0.17	0.31	0.01	\$26.27	0	0.21	0.01	\$11.21
90472	0.15	0.13	0.01	\$15.51	0	0.14	0.01	\$7.59
90473	-	-	-	-	-	-	-	-
90474	-	-	-	-	-	-	-	-
90780	0.17	2.15	0.07	\$127.12	0.17	2.15	0.07	\$121.13
90781	0.17	0.46	0.04	\$35.35	0.17	0.46	0.04	\$32.57
90782	0.17	0.32	0.01	\$26.81	0.17	0.32	0.01	\$24.31
90783	0.17	0.31	0.02	\$26.61	0.17	0.32	0.02	\$24.65
90784	0.17	0.8	0.04	\$53.61	0.17	0.8	0.04	\$50.19
90788	0.17	0.26	0.01	\$23.59	0.17	0.27	0.01	\$21.72
96400	0.17	1.12	0.01	\$69.75	0.17	1.12	0.01	\$65.76
96405	0.52	2.3	0.03	\$152.90	0.52	2.35	0.02	\$145.04
96408	0.17	2.91	0.06	\$167.57	0.17	2.91	0.06	\$160.16
96410	0.17	4.16	0.08	\$235.37	0.17	4.16	0.08	\$225.59
96412	0.17	0.74	0.07	\$51.42	0.12	0.74	0.07	\$45.91
96414	0.17	5.22	0.08	\$292.27	0.17	5.22	0.08	\$280.50
96425	0.17	4.47	0.08	\$252.01	0.17	4.73	0.08	\$255.12
96520	0.21	3.76	0.06	\$215.39	0.17	3.94	0.06	\$213.52
96530	0.21	2.64	0.06	\$155.26	0.17	2.86	0.06	\$157.57

Demonstration Project Analysis - Evaluation CMS Drug Reimbursement Methodology Changes

a) Analysis of All Provider Types and Specialists administering CPT Codes 96408 and 96410

Category	Number of Members	Number of Claims	Number of Payments	Number of Payments	Number of Payments
FEP	\$93,880	\$70,395	\$48,930	\$23,485	\$23,485
HMO	\$661,960	\$498,470	\$330,980	\$165,480	\$165,480
INDEMNITY	\$1,040	\$780	\$520	\$260	\$260
MEDICARE RISK	\$117,260	\$87,945	\$58,630	\$29,315	\$29,315
OTHER	\$161,720	\$121,290	\$80,860	\$40,430	\$40,430
POS	\$147,940	\$110,955	\$73,970	\$36,985	\$36,985
PPO	\$139,620	\$104,716	\$69,810	\$34,905	\$34,905

Totals: **\$1,323,400** **\$992,550** **\$661,700** **\$330,860**

b) Analysis of Oncology Provider Type and Specialty 2059 administering CPT Codes 96408 and 96410

Category	Number of Members	Number of Claims	Number of Payments	Number of Payments	Number of Payments
FEP	\$73,680	\$55,185	\$36,790	\$18,395	\$18,395
HMO	\$568,280	\$424,710	\$283,140	\$141,570	\$141,570
INDEMNITY	\$520	\$390	\$260	\$130	\$130
MEDICARE RISK	\$81,120	\$60,840	\$40,560	\$20,280	\$20,280
OTHER	\$144,300	\$108,225	\$72,150	\$36,075	\$36,075
POS	\$114,400	\$85,800	\$57,200	\$28,600	\$28,600
PPO	\$107,120	\$80,340	\$53,560	\$26,780	\$26,780

Totals: **\$1,087,320** **\$815,490** **\$543,660** **\$271,830**

CMS Demonstration Project Analysis Methodology Outline:

- 1) Analysis performed on the data set used for "Drug Administration Analysis".
- 2) Members were identified if they had claims for CPT Codes 96408 "Chemotherapy Push Technique" or 96410 "Chemotherapy Infusion Technique".
- 3) A per encounter fee of \$130.00 was applied to these members based on Date of Service.
- 4) The number was annualized using a factor of 2.
- 5) Since not all chemotherapy patients meet the criteria as set forth by Medicare (suffering from nausea, fatigue and pain) we included a step down of 75%, 50% and 25% of these Members participating in the program.

Year	Specialty	Visits	Top 5 Diagnoses	Top 5 Procedures	Top 5 Medications	Top 5 Referrals
2019	Oncology/Hematology	\$6,874,292	\$1,222,922	\$4,072,463	\$1,669,960	\$1,669,960
2020	Internal Medicine	\$1,929,242	\$740,293	\$1,188,949	\$1,188,949	\$1,188,949
2021	Obstetrics/Gynecology	\$183,022	\$46,623	\$201,080	\$201,080	\$201,080
2022	Rheumatology	\$449,853	\$154,611	\$300,756	\$300,756	\$300,756
2023	Family Practice	\$553,281	\$253,332	\$300,756	\$300,756	\$300,756
2024	Allergy & Immunology	\$245,167	\$71,566	\$173,601	\$173,601	\$173,601
2025	Pediatric	\$6,642,266	\$3,527,707	\$3,114,559	\$3,114,559	\$3,114,559
2026	General Practice	\$71,099	\$40,146	\$30,953	\$30,953	\$30,953
2027	Urology	\$125,440	\$71,371	\$54,069	\$54,069	\$54,069
2028	Gastroenterology	\$113,500	\$40,863	\$72,637	\$72,637	\$72,637
2029						
2030	Top 10 Totals:	\$17,187,163	\$5,669,433	\$10,517,730	\$10,517,730	\$10,517,730
2031	All other Types and Specialties:	\$577,137	\$247,626	\$329,511	\$329,511	\$329,511
2032	Total Patient	\$17,764,300	\$5,917,059	\$10,847,241	\$10,847,241	\$10,847,241

Drug	Generic Name	Strength	Unit	Manufacturer	Price per Unit	Price per 30 Units	Price per 90 Units	Price per 180 Units	Price per 360 Units	Price per 720 Units	Price per 1440 Units	Price per 2880 Units	Price per 5760 Units	Price per 11520 Units	Price per 23040 Units	Price per 46080 Units	Price per 92160 Units	Price per 184320 Units	Price per 368640 Units	Price per 737280 Units	Price per 1474560 Units	Price per 2949120 Units	Price per 5898240 Units	Price per 11796480 Units	Price per 23592960 Units	Price per 47185920 Units	Price per 94371840 Units	Price per 188743680 Units	Price per 377487360 Units	Price per 754974720 Units	Price per 1509949440 Units	Price per 3019898880 Units	Price per 6039797760 Units	Price per 12079595520 Units	Price per 24159191040 Units	Price per 48318382080 Units	Price per 96636764160 Units	Price per 193273528320 Units	Price per 386547056640 Units	Price per 773094113280 Units	Price per 1546188226560 Units	Price per 3092376453120 Units	Price per 6184752906240 Units	Price per 12369505812480 Units	Price per 24739011624960 Units	Price per 49478023249920 Units	Price per 98956046499840 Units	Price per 197912092999680 Units	Price per 395824185999360 Units	Price per 791648371998720 Units	Price per 1583296743997440 Units	Price per 3166593487994880 Units	Price per 6333186975989760 Units	Price per 12666373951979520 Units	Price per 25332747903959040 Units	Price per 50665495807918080 Units	Price per 101330991615836160 Units	Price per 202661983231672320 Units	Price per 405323966463344640 Units	Price per 810647932926689280 Units	Price per 1621295865853378560 Units	Price per 3242591731706757120 Units	Price per 6485183463413514240 Units	Price per 12970366926827028480 Units	Price per 25940733853654056960 Units	Price per 51881467707308113920 Units	Price per 103762935414616227840 Units	Price per 207525870829232455680 Units	Price per 415051741658464911360 Units	Price per 830103483316929822720 Units	Price per 1660206966633859645440 Units	Price per 3320413933267719290880 Units	Price per 6640827866535438581760 Units	Price per 13281655733070877163520 Units	Price per 26563311466141754327040 Units	Price per 53126622932283508654080 Units	Price per 106253245864567017309120 Units	Price per 2125064917291340346182240 Units	Price per 4250129834582680692364480 Units	Price per 8500259669165361384728960 Units	Price per 17000519338326722768457920 Units	Price per 34001038676653445536915840 Units	Price per 68002077353306891073831680 Units	Price per 136004154706613782147667360 Units	Price per 272008309413227564295334720 Units	Price per 544016618826455128590669440 Units	Price per 1088033237652910257181338880 Units	Price per 2176066475305820514362677760 Units	Price per 43521329506116410257181338880 Units	Price per 87042659012232820514362677760 Units	Price per 1740853180244604257181338880 Units	Price per 34817063604892085143626777760 Units	Price per 69634127209784170257181338880 Units	Price per 139268254419568340257181338880 Units	Price per 278536508839136680257181338880 Units	Price per 557073017678273360257181338880 Units	Price per 1114146035356546720257181338880 Units	Price per 222829207071309344257181338880 Units	Price per 445658414142618688257181338880 Units	Price per 891316828285237376257181338880 Units	Price per 178263365657047475257181338880 Units	Price per 3565267312940949504257181338880 Units	Price per 7130534625881899008257181338880 Units	Price per 14261069257637988016257181338880 Units	Price per 2852213851527597603257181338880 Units	Price per 57044277030551952064257181338880 Units	Price per 114088554061103904128257181338880 Units	Price per 228177108122207808257181338880 Units	Price per 456354216244416257181338880 Units	Price per 91270843248883251257181338880 Units	Price per 18254168649776650257181338880 Units	Price per 3650833729955330051257181338880 Units	Price per 730166745991066010257181338880 Units	Price per 146033349198213202057181338880 Units	Price per 2920666983964264040257181338880 Units	Price per 5841333967928528080257181338880 Units	Price per 11682667857857256160257181338880 Units	Price per 23365335715714512320257181338880 Units	Price per 46730671431429024640257181338880 Units	Price per 93461342862858049280257181338880 Units	Price per 186922685725716163840257181338880 Units	Price per 373845371451432326720257181338880 Units	Price per 747690742902864653440257181338880 Units	Price per 1495381485805729326880257181338880 Units	Price per 29907629716114586567680257181338880 Units	Price per 59815259432229173135360257181338880 Units	Price per 1196305188644423066720257181338880 Units	Price per 23926103772888461333440257181338880 Units	Price per 47852207545776922666880257181338880 Units	Price per 95704415091553445333760257181338880 Units	Price per 191408831831106890667520257181338880 Units	Price per 382817663662213781333440257181338880 Units	Price per 76563532732442706666720257181338880 Units	Price per 153127065464884813333440257181338880 Units	Price per 306254130929769626666720257181338880 Units	Price per 612508261839539253333440257181338880 Units	Price per 1225016523678778506666720257181338880 Units	Price per 24500330473575570133333440257181338880 Units	Price per 4900066094715114026666672025718133
------	--------------	----------	------	--------------	----------------	--------------------	--------------------	---------------------	---------------------	---------------------	----------------------	----------------------	----------------------	-----------------------	-----------------------	-----------------------	-----------------------	------------------------	------------------------	------------------------	-------------------------	-------------------------	-------------------------	--------------------------	--------------------------	--------------------------	--------------------------	---------------------------	---------------------------	---------------------------	----------------------------	----------------------------	----------------------------	-----------------------------	-----------------------------	-----------------------------	-----------------------------	------------------------------	------------------------------	------------------------------	-------------------------------	-------------------------------	-------------------------------	--------------------------------	--------------------------------	--------------------------------	--------------------------------	---------------------------------	---------------------------------	---------------------------------	----------------------------------	----------------------------------	----------------------------------	-----------------------------------	-----------------------------------	-----------------------------------	------------------------------------	------------------------------------	------------------------------------	------------------------------------	-------------------------------------	-------------------------------------	-------------------------------------	--------------------------------------	--------------------------------------	--------------------------------------	---------------------------------------	---------------------------------------	---------------------------------------	---------------------------------------	--	--	--	---	---	---	--	---	---	---	--	--	--	---	---	---	--	--	---	---	--	---	---	--	--	--	---	--	--	--	--	---	---	--	---	--	---	--	---	---	---	---	--	--	---	---	--	--	--	--	---	---	---	--	---	---	--	---	---	---	--	--	---	--	--	--	---	--	--

Drug Specific Impact on Oncology/Hematology Type/Specialty Annualized Data Sort Based on Allowed Amounts

Drug	Quantity	Allowed Amount	Actual Amount	Impact	Impact %
J9288 Pentostatin Injection	10	\$2,162	\$18,555	\$16,377	18.555%
Q0180 Dolasetron mesylate oral	206	\$23,572	\$17,266	\$14,921	-31.15%
J9370 Vincristine sulfate 1 MG Inj	388	\$22,582	\$13,508	\$13,184	-55.28%
J9181 Etoposide 10 MG Inj	6,144	\$121,623	\$9,833	\$10,840	-85.28%
J9140 Docetaxel 200 MG Inj	470	\$18,898	\$10,271	\$10,227	-26.10%
J9062 Cisplatin 50 MG Injection	128	\$44,170	\$10,020	\$9,997	-47.19%
J1190 Dexamethasone HCl Injection	40	\$11,920	\$9,359	\$8,959	-9.73%
J9091 Cyclophosphamide 1.0 grm Inj	182	\$14,888	\$9,187	\$8,753	-41.22%
J7030 Normal saline solution infus	998	\$14,803	\$9,117	\$9,110	-93.25%
J9180 Fluorouracil Injection	4,048	\$22,096	\$8,478	\$8,379	9.18%
J9182 Etoposide 100 MG Inj	442	\$95,787	\$8,470	\$7,909	-62.16%
J1100 Dexamethasone sodium phos	59,738	\$199,298	\$7,475	\$5,863	-9.09%
J0886 Capecitabine sodium Injection	480	\$11,264	\$7,162	\$7,162	-3.45%
J9178 Inj, epirubicin hcl, 2 mg	220	\$9,480	\$6,081	\$5,804	-8.86%
J1758 Iron sucrose Injection	6,200	\$110,356	\$5,330	\$5,330	-40.00%
J9360 Vinorelbine sulfate Inj	1,548	\$15,175	\$5,295	\$4,861	-80.57%
J7042 5% dextrose/normal saline	502	\$8,840	\$5,245	\$5,158	-96.66%
J9090 Cyclophosphamide 500 MG Inj	158	\$7,644	\$3,619	\$3,612	-53.50%
J1200 Diphenhydramine hcl Inj	2,010	\$9,420	\$3,064	\$3,216	-43.75%
J7080 5% dextrose/water	264	\$4,735	\$3,247	\$2,989	-37.48%
J2897 Alleplase recombinant	80	\$5,361	\$2,936	\$2,755	-17.63%
J1642 Inj heparin sodium per 10 u	44,714	\$40,853	\$2,621	\$2,236	-20.00%
Q0178 Ondansetron HCl 8mg oral	40	\$4,840	\$1,806	\$1,567	-5.85%
J9150 Daunorubicin	24	\$5,280	\$1,782	\$1,782	-64.50%
J2780 Rantidline hydrochloride Inj	746	\$6,141	\$1,198	\$1,074	-34.03%
J9375 Vincristine sulfate 2 MG Inj	16	\$1,504	\$1,087	\$1,074	-85.23%
J9280 Mitomycin 5 MG Inj	16	\$2,640	\$1,021	\$1,021	-62.98%
J9100 Cytarabine hcl 100 MG Inj	126	\$1,312	\$832	\$1,032	-79.85%
J9260 Methotrexate sodium Inj	158	\$1,452	\$751	\$751	-53.47%
J2930 Methylprednisolone Injection	280	\$3,393	\$674	\$634	39.58%
J2597 Inj desmopressin acetate	194	\$2,716	\$668	\$668	-18.84%
J9320 Streptozocin Injection	4	\$1,144	\$566	\$528	26.33%
J1650 Inj enoxaparin sodium	50	\$90	\$521	\$305	-14.43%
J2060 Lorazepam Injection	134	\$2,224	\$450	\$421	-51.91%
J1940 Furosemide Injection	444	\$92	\$435	\$435	-59.18%
J6280 Mitomycin 20 MG Inj	2	\$1,826	\$415	\$415	-68.02%
J2150 Mannitol Injection	102	\$644	\$334	\$334	-63.18%
J1380 Diphenhydramine Injection	36	\$987	\$324	\$324	-47.06%
J1644 Inj heparin sodium per 1000u	806	\$4,408	\$322	\$322	-42.50%
J0610 Calcium gluconate-Injection	222	\$528	\$276	\$276	-62.38%
J9200 Flouxuridine Injection	2	\$520	\$274	\$274	-46.88%
J3475 Inj magnesium sulfate	846	\$3,376	\$243	\$195	-56.52%
J0460 Atropine sulfate Injection	256	\$1,046	\$211	\$203	-30.49%

Drug and Administration Code Analysis - Total Type and Specialty Impact Analysis									
Analysis of the Impact of the Implementation of Medicare Drug and Drug Administration pricing changes									
Year	Drug Code	Drug Name	Drug Type	Specialty	2019	2020	2021	2022	2023
2019	0001	Aspirin	Analgesic	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2020	0002	Ibuprofen	Analgesic	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2021	0003	Acetaminophen	Analgesic	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2022	0004	Metformin	Antidiabetic	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2023	0005	Lisinopril	Antihypertensive	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2024	0006	Atorvastatin	Lipid-lowering	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2025	0007	Simvastatin	Lipid-lowering	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2026	0008	Warfarin	Anticoagulant	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2027	0009	Insulin	Antidiabetic	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2028	0010	Levothyroxine	Thyroid hormone	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2029	0011	Fluoxetine	Antidepressant	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2030	0012	Sertraline	Antidepressant	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2031	0013	Escitalopram	Antidepressant	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2032	0014	Clonidine	Antihypertensive	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2033	0015	Hydrochlorothiazide	Antihypertensive	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2034	0016	Furosemide	Diuretic	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2035	0017	Acyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2036	0018	Valacyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2037	0019	Acyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2038	0020	Valacyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2039	0021	Acyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2040	0022	Valacyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2041	0023	Acyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2042	0024	Valacyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2043	0025	Acyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2044	0026	Valacyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2045	0027	Acyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2046	0028	Valacyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2047	0029	Acyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2048	0030	Valacyclovir	Antiviral	Primary Care	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
2049	0031	Acyclovir	Antiviral	Primary Care					

Year	Specialty	Physicians	Patients	Revenue	Net Income	Operating Expenses	Capital Expenses	Depreciation	Interest	Taxes	Other	Total
20059	Oncology/Hematology	31,457,860	17,972,667	17,461,073	17,897,637							
20060	Oncology	\$4,814,666	\$3,787,786	\$3,621,837	\$3,721,323							\$13,680,714
20061	Internal Medicine	\$8,461,321	\$5,860,640	\$5,679,397	\$5,777,537							\$1,918,398
20062	Allergy & Immunology	\$2,430,699	\$1,997,979	\$1,970,748	\$1,976,254							\$4,432,738
20063	Rheumatology	\$5,492,018	\$4,102,049	\$4,052,935	\$4,121,317							\$1,018,441
20064	Dermatology	\$1,259,017	\$642,875	\$619,832	\$657,366							\$3,333,336
20065	Gastroenterology	\$1,542,308	\$1,083,595	\$1,060,152	\$1,071,737							\$420,195
20066	Cardiovascular Disease	\$282,474	\$136,076	\$108,001	\$241,305							\$860,074
20067	Orthopedic Surgery	\$1,287,789	\$709,808	\$644,401	\$741,555							\$144,541
20068	Nephrology	\$297,316	\$231,644	\$222,312	\$231,206							\$684,361
												\$179,374
	Top 10 Totals:	\$57,326,467	\$38,526,119	\$35,440,669	\$36,437,236							\$26,632,472
	All other Types and Specialties:	\$2,467,386	\$1,516,226	\$1,418,235	\$1,733,939							\$1,426,775
	Total Income:	\$59,793,853	\$39,042,345	\$36,858,905	\$38,171,175							\$28,059,251
												\$10,722,218
												\$25,937,033

